CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$39.10+0.17 (+0.44%)
Close on Nov 20, 2026Market cap $3.78BP/E –Yield –
CRISPR Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
CRISPR Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$371.33M. For fiscal 2025 it was -$345.93M. The highest annual figure on record is $457.27M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$345.93M | – |
| FY2024 | Dec 31, 2024 | -$144.68M | – |
| FY2023 | Dec 31, 2023 | -$269.85M | – |
| FY2022 | Dec 31, 2022 | -$532.93M | -216.5% |
| FY2021 | Dec 31, 2021 | $457.27M | – |
| FY2020 | Dec 31, 2020 | -$256.72M | -613.5% |
| FY2019 | Dec 31, 2019 | $49.99M | – |
| FY2018 | Dec 31, 2018 | -$99.01M | – |
| FY2017 | Dec 31, 2017 | -$77.91M | – |
| FY2016 | Dec 31, 2016 | -$55.88M | -195.9% |
| FY2015 | Dec 31, 2015 | $58.27M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$84.15M | – |
| Q1 FY2026 | Mar 31, 2026 | -$109.40M | – |
| Q4 FY2025 | Dec 31, 2025 | -$93.07M | – |
| Q3 FY2025 | Sep 30, 2025 | -$84.71M | – |
| Q2 FY2025 | Jun 30, 2025 | -$114.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$54.15M | -149.7% |
| Q4 FY2024 | Dec 31, 2024 | -$50.29M | – |
| Q3 FY2024 | Sep 30, 2024 | -$107.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$96.29M | – |
| Q1 FY2024 | Mar 31, 2024 | $109.03M | +1799.5% |
| Q4 FY2023 | Dec 31, 2023 | -$96.81M | – |
| Q3 FY2023 | Sep 30, 2023 | -$41.97M | – |
| Q2 FY2023 | Jun 30, 2023 | -$136.80M | – |
| Q1 FY2023 | Mar 31, 2023 | $5.74M | – |
| Q4 FY2022 | Dec 31, 2022 | -$119.52M | – |
| Q3 FY2022 | Sep 30, 2022 | -$111.24M | – |
| Q2 FY2022 | Jun 30, 2022 | -$151.59M | -119.5% |
| Q1 FY2022 | Mar 31, 2022 | -$150.59M | – |
| Q4 FY2021 | Dec 31, 2021 | -$95.22M | – |
| Q3 FY2021 | Sep 30, 2021 | -$118.38M | – |
| Q2 FY2021 | Jun 30, 2021 | $778.55M | – |
| Q1 FY2021 | Mar 31, 2021 | -$107.69M | – |
| Q4 FY2020 | Dec 31, 2020 | -$87.45M | -3707.7% |
| Q3 FY2020 | Sep 30, 2020 | -$81.22M | -162.0% |
| Q2 FY2020 | Jun 30, 2020 | -$32.88M | – |
| Q1 FY2020 | Mar 31, 2020 | -$55.17M | – |
| Q4 FY2019 | Dec 31, 2019 | $2.42M | – |
| Q3 FY2019 | Sep 30, 2019 | $130.96M | – |
| Q2 FY2019 | Jun 30, 2019 | -$38.56M | – |
| Q1 FY2019 | Mar 31, 2019 | -$44.83M | – |
| Q4 FY2018 | Dec 31, 2018 | -$29.37M | – |
| Q3 FY2018 | Sep 30, 2018 | -$20.66M | – |
| Q2 FY2018 | Jun 30, 2018 | -$25.74M | – |
| Q1 FY2018 | Mar 31, 2018 | -$23.24M | – |
| Q4 FY2017 | Dec 31, 2017 | -$15.05M | – |
| Q3 FY2017 | Sep 30, 2017 | -$18.86M | – |
| Q2 FY2017 | Jun 30, 2017 | -$17.30M | – |
| Q1 FY2017 | Mar 31, 2017 | -$26.70M | – |
| Q4 FY2016 | Dec 31, 2016 | -$17.19M | – |
| Q3 FY2016 | Sep 30, 2016 | -$13.79M | – |
See a number that looks wrong?